ICML 2023 Meeting: CFT7455 in NHL Preclinical Presentation
CFT7455: A novel IKZF1/3 degrader, demonstrates potent anti-tumor activity in peripheral and CNS models of non-Hodgkins lymphoma as a single... | June 16, 2023
Source: marketscreener.com